StockData

Jyong Biotech Ltd. (MENS) company profile

MENSNasdaqPharmaceutical Preparations
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on May 15, 2026Score 0/30
$1.86+0.06 (+3.33%)

Close on Nov 18, 2026Market cap $141.41MP/E –Yield –

About Jyong Biotech

Pharmaceutical Preparations, SIC 2834

Jyong Biotech Ltd. is a clinical-stage biopharmaceutical company focused on the development of botanical drug products. The company's primary focus is on advancing its core drug candidate, Botreso, which is undergoing clinical development for the initial treatment of benign prostatic hyperplasia and lower urinary tract symptoms (BPH/LUTS). In addition to Botreso, the company explores other potential indications, such as prostate cancer prevention, as well as candidates designated as PCP and IC. Its future customer base encompasses prospective patients, healthcare providers, and third-party payors within the medical community.

All of the company's key drug candidates remain in preclinical or clinical development phases without commercial sales or marketing approval. The company conducts research and clinical development activities across multiple jurisdictions, including the United States and Taiwan, while considering broader international regulatory pathways. Jyong Biotech Ltd. maintains its principal executive offices and headquarters in New Taipei City, Taiwan, and is incorporated under the laws of the Cayman Islands.

Summary of the business section of Jyong Biotech's latest annual report, written by StockData.

Company profile

Company

Legal name
Jyong Biotech Ltd.
Headquarters
New Taipei City, Taiwan
Address
23f-3, No.95, Sec. 1, Xintai 5th Rd., Xizhi Dist.
Phone
(8862) 27325205
Employees
15, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
E9
Auditor
WWC, P.C, San Mateo, California

Stock & identifiers

Ticker
MENS
Exchange
Nasdaq
IPO date
Jun 18, 2025
Shares outstanding
76M, Dec 31, 2025
Filer category
Non-accelerated filer<br>Emerging growth company
SEC CIK
1954488
CUSIP
G83116106
FIGI
BBG01HZQMX71
Share class FIGI
BBG01HZQMY60
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Fu-Feng KuoCEO, Director25,349,500
Wei (Vivi) ZhangCFO–
Ming Tsan HsuDirector3,000
Hung-Shu FanDirector–
Feng-Lin HsuDirector3,000
Pang-Chieh ChiDirector–

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jun 18, 2025
Offer price
$7.50
Exchange
Nasdaq
First trading day
Jun 17, 2025
First-day close
$10.11+34.8%
Lock-up ends (est.)
Dec 14, 2025

“The initial public offering price of our ordinary shares is US$7.50 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Corporate history

Events identified from SEC filings

See a number that looks wrong?